Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Head & Neck 2Breast 2Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Steroids × Plasma cell × Clear all
NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡